Novapep Pty Ltd

Developing novel peptides for the treatment of atopic dermatitis, inflammatory bowel disease and sepsis, where there are large unmet medical needs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Sydney NSW, Australia
  • Currency AUD
  • Founded October 2016
  • Employees 1
  • Incorporation Type Other
  • Website novapep.com

Company Summary

Prof John Griffin of the Scripps Research Instititute has invented biparetide, a peptide which cheap and ideal for topical and oral administration. Novapep has licensed the patents to 2039.

Strong efficacy results obtained for biparetide in IBD. It is as effective as the gold standard treatment anti-TNF⍺, an expensive injectable biologic and is more effective than corticosteroids, which can't be used for long without serious side-effects.

Team

  • Rob Antulov, BE (Hons), MBA
    Chairman

    * Experienced tech corporate adviser, with over 30 years' experience.

    * Advised on over 60 corporate transactions, in media, tech and biotech.

    * Current Chairman of Prokardia Therapeutics.

    * Formerly Director of Strategy at Fairfax Media, senior marketing and strategy executive with Coca-Cola, and strategy consultant with Strategy& (Booz & Co).

  • Jay Hennock
    CEO

    * Over 30 years in corporate advisory services with Citibank, Bank of America.

    * Co-founded Access Systems and sold to International Gaming Technology Inc.

    * Co-founder & CFO of Nuon Therapeutics Inc. and founder and CEO of Bioatrix.

    * Sold Bioatrix to ZZ Biotech LLC - www.zzbiotech.com and is a Director and shareholder of ZZ Biotech.

  • Evan Siegel
    Strategy, Regs, Tox and CMC Consultant

    * CEO and President of Ground Zero Pharmaceuticals, Inc. - www.groundzerous.com

    * Principal Regulatory Scientist & Director Regulatory Services, Quintiles Inc.

    * Director/Sr. Director, Regulatory Affairs and Corporate Compliance, Syntex, Inc. and Astra Inc.

    * Director of Pharmacology and Tox, Pharmaceutical Trade Association.

    * Reviewing Toxicologist, US FDA; Supervising Toxicologist, California Food and Drug Branch.

  • Tom Gumley BSc (Hons), PhD
    IP and Patenting Consultant

    * Life sciences patent consultant with over 20+ years’ experience in biotech and pharma R&D.

    * Formerly Principal, FPA Patent Attorneys and Partner at Freehills Patent Attorneys in Melbourne.

  • Professor John Griffin BS, PhD
    Chief Scientific Officer

    * Professor, Dept of Molecular Medicine, The Scripps Research Institute at La Jolla.

    * NMR studies of peptide and protein structure at the French AEC Laboratory.

    * Published over 350 papers in Activated Protein C and APC mutants.

    * Inventor of 3K3A-Activated Protein C and TR47 - the PAR1 agonist peptide.

    * Co-inventor of the G10 PAR1-PAR3 structure.

    * Holds appointment at the Department of Medicine, UC San Diego

  • Professor Christopher Jackson BAppSc, MAppSc, PhD
    Program Lead - Dermatitis and Burns

    * Professor, Regenerative Science and Medicine, Kolling Institute, University of Sydney.

    * Director, Sutton Laboratories, Institute of Bone and Joint Research at the Royal North Shore Hospital.

    * Co-inventor of APC as a therapy in inflammation and skin disorders and publisher of over 90 papers on the subject.

  • Professor Silvio Danese MD, PhD
    Program Lead - Inflammatory Bowel Disease

    * Professor of Gastroenterology IRCCS San Raffaele Hospital and of Gastroenterology at the Vita-Salute San Raffaele University.

    * Published more than 300 research articles in peer-reviewed journals.

    * President of European Crohn’s and Colitis Organization (ECCO) and Secretary and Chair of the Clinical Trial task force of the International Organization of IBD (IOIBD).

  • Laurent Mosnier
    Program Lead - Cerebral Malaria

    * Professor, Department of Molecular Medicine, The Scripps Research Institute La Jolla

    * Inventor of P3R - the PAR3 agonist peptide.

    * Co-inventor of the G10 PAR1-PAR3 structure.

    * Published extensively in APC and cerebral malaria.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free